Dx Deals: New Deal Expands Reach of Oral Cancer Test to Dental Practices
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
While only time will tell how bad the ultimate damage turns out to be, it appears for now at least that the industry has dodged a bullet.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
Agency’s annual report to Congress concludes that providers are doing just fine and don’t need a big bump in pay at this time.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
With COVID-19 testing demand all but dried up, labs will have to make—or at least contemplate making—significant changes to their business.
Companies in the COVID-19 diagnostic products market will need to decide whether to wind down their EUA-based investments.
Though Q4 earnings in the lab industry took a beating as predicted, the earnings picture wasn’t nearly as bleak as many had feared.
The health plan issued a new policy expanding coverage of molecular genetic tests for personalized cancer diagnosis, prognosis, and treatment.
Genomics software developer Allelica to collaborate with Taiwanese precision medicine firm to develop a multi-ancestry breast cancer test.